A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 May 2017
At a glance
- Drugs Ribavirin (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C; Liver cirrhosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 02 May 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.
- 22 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2017.